American journal of veterinary research · 2026
Vertebral left atrial ventral: a new prognostic marker in dogs with mitral valve disease.
СтатьяObservational Study, VeterinaryНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Beluque Tamyris, Endrighi Mariangela, Lucina Stephany Buba, Rodrigues Alessandra, Braz Jaislane Bastos, Zacché Evandro, de Oliveira Leonardo Bianchi, Froes Tilde Rodrigues, Sousa Marlos Gonçalves
Аннотация
OBJECTIVE: To compare previously described radiographic measurements to identify dogs in stage B2, cutoff values, propose a new measurement and evaluate their ability to predict survival in dogs with mitral valve disease (MVD).
METHODS: This observational, retrospective, and prospective study included dogs without heart disease (control) or diagnosed with MVD by Doppler echocardiography. Radiographic measurements included left atrial width (LAwidth), radiographic left atrial dimension (RLAD), vertebral left atrial size (VLAS), modified VLAS (M-VLAS), vertebral left atrial ventral (VLAV), and vertebral heart score (VHS). All dogs underwent complete echocardiographic and radiographic examinations. Dogs with hemivertebrae, cardiac or pulmonary neoplasia, or poor-quality examinations were excluded. Examinations performed between November 2017 and April 2024 were evaluated.
RESULTS: Examinations were evaluated in 191 dogs. VLAS, M-VLAS, LAwidth, and RLAD differed between stages B1, B2, and C/D. VLAV differed between control and stage B1 from stages B2 and C/D. VLAV accurately identified dogs with stage B2 MVD, showing good diagnostic performance (AUC, 0.82; 95% CI, 0.76-0.88), and was similar to the other measurements. Cutoff values for identifying left cardiomegaly were defined for all measures (VLAS > 2.48; M-VLAS > 3.4; LAwidth > 2.11; RLAD > 2.7; VLAV > 2.99). Repeatability and reproducibility were good to excellent.
CONCLUSIONS: VLAS and M-VLAS reliably identified increased LA/Ao ratio and suspected stage B2 MVD. Higher values of VLAS, M-VLAS, LAwidth, and VLAV were associated with shorter survival, with VLAV ≥ 3.0 indicating an unfavorable outcome.
CLINICAL RELEVANCE: These measures may be considered to screen which patients will undergo echocardiography and to assist in predicting survival time.
METHODS: This observational, retrospective, and prospective study included dogs without heart disease (control) or diagnosed with MVD by Doppler echocardiography. Radiographic measurements included left atrial width (LAwidth), radiographic left atrial dimension (RLAD), vertebral left atrial size (VLAS), modified VLAS (M-VLAS), vertebral left atrial ventral (VLAV), and vertebral heart score (VHS). All dogs underwent complete echocardiographic and radiographic examinations. Dogs with hemivertebrae, cardiac or pulmonary neoplasia, or poor-quality examinations were excluded. Examinations performed between November 2017 and April 2024 were evaluated.
RESULTS: Examinations were evaluated in 191 dogs. VLAS, M-VLAS, LAwidth, and RLAD differed between stages B1, B2, and C/D. VLAV differed between control and stage B1 from stages B2 and C/D. VLAV accurately identified dogs with stage B2 MVD, showing good diagnostic performance (AUC, 0.82; 95% CI, 0.76-0.88), and was similar to the other measurements. Cutoff values for identifying left cardiomegaly were defined for all measures (VLAS > 2.48; M-VLAS > 3.4; LAwidth > 2.11; RLAD > 2.7; VLAV > 2.99). Repeatability and reproducibility were good to excellent.
CONCLUSIONS: VLAS and M-VLAS reliably identified increased LA/Ao ratio and suspected stage B2 MVD. Higher values of VLAS, M-VLAS, LAwidth, and VLAV were associated with shorter survival, with VLAV ≥ 3.0 indicating an unfavorable outcome.
CLINICAL RELEVANCE: These measures may be considered to screen which patients will undergo echocardiography and to assist in predicting survival time.